Member Info for goldust88

Well I saw a big director sell a few days back so decided to follow suit and bank a good profit.
I am thinking that the price MAY pull back in the short term (as they say -sell in May) and then pick up again late summer. We will see as this company is a great one.

Liberum now upgraded FUM to 80p on latest news
Any more deals and they will up price more.

Well-excellent results even better than I expected. You would not think that there had be any pandemic looking at their results and forecasts. The future here looks even better every time they report.
Could well get tip in the press with the great prospects they have going forward.
A very well run company with a great future.

Well Liam just go and sit in the freezer then it might make you feel better, at least we could lock the door and bring back some sense on the thread.

Liam if you studied the information more closely on MED you will see it does not just warm.
The initial effect is cooling and then goes into a warming mode. This is quite unlike any other product. Thats what makes it unique. So if you want to keep bashing please keep your facts right and do some more research.

With Futura's results day next Wednesday we can look forward to getting up dates on Futura's progress
James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results, which will be made available within the investor centre section of the Company's website.
The Results webcast will include an outline of the small confirmatory clinical study FM71, EU & FDA regulatory approval for MED3000 and Futura's commercialisation collaborations.
Any news of further deals will propel the shares upward.
So just ignore Liam's negative postings and the laughable idea that he owns share and concentrate on the massive potential
that Futura have and if you haven't bought any shares yet-I would suggest that now is the time to buy a few and enjoy the great rise ahead.
Carry on FUMing.

The taking up of the warrants is a good indicator that Riverwood clearly have got some great interest in Med 3000 in China and Asia and one can expect more great news from then shortly.
The extra cash also places Futura in a better position as they move forward.
Expect more news in the next few days.
This small bit of news has sent the price up 7% in the last 10 minutes of trading so any substantial news will see a big jump.

It says---" Results webcast will include an outline of the small confirmatory clinical study FM71, EU & FDA regulatory approval for MED3000 and Futura's commercialisation collaborations ".
So news of future deals or deals done will be given on the day.
Looks like some great news lined up for this day in14 days time !

Liambooth-you have a lot to say and I see you setting yourself up as an "expert" on here.
So have you any shares ?
Or are you just stirring?

Nice rise today to 58p
Later in the year I'm expecting to get past 158p and that will be very nice.
Roll on the news

ADVFN LEVEL 2

56.5 ON LEVEL 2 and going up

Ground Hog Day---I shouldn't worry about how much cash they have as it is certain any future deals will pay enough cash up front not only that but last year in March they received over £4 million in Tax Credits and one can expect something similar again shortly.
So n0 need to raise any funds !

News of more licensing deals will be announced over the next few weeks, as every one is announced the share price will jump.
Its still a tiddler and a once in a lifetime chance to really make some money.

Currently Futura is valued at only £120 million.
They will be licencing MED 2000 out around the world for a down payment and royalty fee income on each sale.
The royalty income on a YEARLY basis could easily become greater than the market cap of £120 million.
A yearly income of £120 Million.
In addition to this they have two other products in the pipeline
TPR 100 . Topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism. This has already gone trials with results showing its greater effectiveness through against any other product.
Current position-In conjunction with its commercial partner, Futura is seeking a scientific advisory meeting with the MHRA to review data and confirm the exact pathway for approval

CBD100 formulation for transdermal delivery of Cannabidiol.
Current position. Patent application submitted for the selected CBD100 novel formulation.
Trials showed compelling in vitro data delivered with up to eight times greater delivery of cannabidiol into the skin with a DermaSys® gel formulation versus an established comparator product.
Patent application submitted for the selected CBD100 novel formulation.
So this year it is quite possible that not only MED2000 but that all three products could be licenced out and providing royalty income.
So putting all this together you can see that Futura could be earning an enormous amount in royalty income in a short time span or is bought out. How many shares have this potential.
My view is that Futura should be many times todays share price and will be when investors catch on to the potential.

The global ED prescription market is estimated to be approximately US$5 billion(1)
RNS 4th march -says this.
That is the PRESCRIPTION MARKET ONLY-not including over the counter (OTC)
So what could the total market be for MED2000 ?
Not only will sufferers be buying this but a lot of folks will want to try it to to enhance their sex life or have a bit of fun.
The share price has way, way to go yet. Annual profits could easily be more than todays company value.

Todays news is superb and the share price has risen accordingly-but this is only the beginning.
They have already signed a deal for selling in China and some asian countries, however as Ken James says in the Proactive interview they have been in discussion with numerous countries all over the world.
As he says their is a massive amount of interest and after the news of the European approval we can expect deal after deal being announced over the weeks ahead.
The potential hear is huge so those who buy or hold the shares will be well rewarded-the journey has just begun.

Analyst Andrew Simms, at the company’s brokers Arden Partners, has estimated that group sales for last year actually improved from £10.9. to £11.7m, while the adjusted pre-tax loss for the year was just £0.1m lower at £0.7m.

However, Simms sees sales lifting to £16.7m this year to end-December and adjusted profits before tax will be some £1.5m, worth 0.5p per share in earnings.

There is a big proviso against any of the expected sales not actually coming through this year, but Simms appears positive in his ‘buy’ stance and his price objective of up to 19p, as compared to last night’s closing 4.2p.

This very profitable trust reports next week and with directors all buying should be in line for a nice increase in share price.
It is followed by Simon Thompson and I would expect him to again to reccomend a purchase as it is very cheap.
Asset value could also see a nice increase.

Trinity Delta Anaylists updated valuation today.

Updated valuation is £181.5m (73.1p/share) Updating our model for the improved visibility on commercialisation strategies lifts our valuation to £181.5m, equivalent to 73.1p a share (71.3p fully diluted), from our previous £153.8m (60.9p per share). Our risk-adjusted DCF model continues to employ conservative assumptions.

And that value is based on news to date-so any further good news will see Futura really move ahead.